MG
VBIO

Marex Group’s Valion Bio VBIO Stock Holding History

Marex Group’s Portfolio VBIO Stock Details VBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.5K Buy
59,263
+18,321
+45% +$18.7K ﹤0.01% 968
2025
Q4 		$59.4K Buy
40,942
+2,549
+7% +$5.82K ﹤0.01% 928
2025
Q3 		$111K Sell
38,393
-890
-2% -$3.07K ﹤0.01% 770
2025
Q2 		$163K Buy
+39,283
New +$169K ﹤0.01% 540

Other funds holding VBIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Marex Group's VBIO Position: Q1 2026 in Review

Marex Group increased its Valion Bio (VBIO) stake by 45% in Q1 2026, buying an estimated $18.7K and bringing the position to 59,263 shares worth $52.5K. The position accounts for ﹤0.01% of the portfolio, ranked #968.

Marex Group first reported a position in VBIO in Q2 2025 and has held it in 4 quarters since. The position peaked at $163K in Q2 2025. 9 funds tracked by Wall St. Rank hold VBIO as of Q1 2026.

  • Marex Group held 59,263 shares of Valion Bio worth $52.5K as of Q1 2026.
  • Marex Group bought 18,321 Valion Bio shares in Q1 2026, an estimated $18.7K.
  • Valion Bio made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #968 holding.
  • Marex Group first reported a position in Valion Bio in Q2 2025 and has held it in 4 quarters since.
  • Marex Group's Valion Bio position peaked at $163K in Q2 2025.
  • 9 funds tracked by Wall St. Rank held Valion Bio as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.